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Bovine tuberculosis (TB) continues to be an intractable problem in many countries,
particularly where “test and slaughter” policies cannot be implemented or where wildlife
reservoirs of Mycobacterium bovis infection serve as a recurrent source of infection for
domestic livestock. Alternative control measures are urgently required and vaccination
is a promising option. Although the M. bovis bacille Calmette-Guérin (BCG) vaccine has
been used in humans for nearly a century, its use in animals has been limited, principally
as protection against TB has been incomplete and vaccination may result in animals
reacting in the tuberculin skin test. Valuable insights have been gained over the past 25
years to optimise protection induced by BCG vaccine in animals and in the development
of tests to differentiate infected from vaccinated animals (DIVA). This review examines
factors affecting the efficacy of BCG vaccine in cattle, recent field trials, use of DIVA
tests and the effectiveness of BCG vaccine in other domestic livestock as well as in
wildlife. Oral delivery of BCG vaccine to wildlife reservoirs of infection such as European
badgers, brushtail possums, wild boar, and deer has been shown to induce protection
against TB and could prove to be a practical means to vaccinate these species at scale.
Testing of BCG vaccine in a wide range of animal species has indicated that it is safe and
vaccination has the potential to be a valuable tool to assist in the control of TB in both
domestic livestock and wildlife.
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INTRODUCTION
Tuberculosis (TB) in domestic livestock and wildlife is caused by Mycobacterium bovis,
Mycobacterium caprae, and other members of the Mycobacterium tuberculosis complex, including
M. tuberculosis whose role in animal TB is being increasingly recognised, particularly in studies
from Africa and Asia (1). Livestock TB continues to be a major economic animal health problem
worldwide. It has been estimated that >50 million cattle are infected worldwide, costing US$3
billion annually (2). The disease is an important zoonosis, causing TB in humans, particularly
through consumption of unpasteurised milk or through co-habitation with infected animals. The
“test and slaughter” bovine TB control programmes introduced in many countries in the mid-
twentieth century achieved dramatic results and a number of countries were able to eradicate this
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disease. However, these control programmes have not been
affordable or socially acceptable in many developing countries,
and more than 94% of the world’s population live in countries in
which control of TB in cattle or buffaloes is limited or absent (3).
Furthermore, a confounding factor in the control of bovine TB in
a number of countries has been the existence of wildlife reservoirs
ofM. bovis infection.
Wildlife serving as maintenance hosts for M. bovis include
the Australian brushtail possum (Trichosurus vulpecula) in New
Zealand, the European badger (Meles meles) in United Kingdom
(UK) and Ireland, white-tailed deer (Odocoileus virginianus) in
Michigan, USA [reviewed in (4)] and Eurasian wild boar (Sus
scrofa) in the Iberian Peninsula, Spain (5). In addition, red deer
(Cervus elaphus) in several parts of Europe (6), African buffalo
(Syncerus caffer) in South Africa (7), and wood bison (Bison
bison athabascae) and wapiti (Cervus elephus manitobensis) in
Canada (8) serve as maintenance hosts for infection in hunting
estates and national parks. These various maintenance hosts act
as sources of infection for domestic species, and in national
parks, infection can spill over to other unique wildlife species
including Iberian lynx (Lynx pardinus), lions (Panthera leo),
leopard (Panthera pardus), and wild dogs (Lycaon pictus). Partial
control has been achieved for some of these maintenance hosts
by minimising contact with livestock, reducing the density of
animals or banning artificial feeding that causes local high
densities of animals (9–11). However, few if any of these control
measures can be implemented for some protected species or
where interference of a natural regulated ecosystem is deemed
undesirable. For these reasons, the development and use of
vaccines for control of TB in both domestic livestock and wild
animals is very appealing.
Although no TB vaccines are currently registered for
protection against TB in domestic livestock, there is renewed
interest in their use from the realisation of the financial impact
of bovine TB on animal health and trade, and due to the difficulty
controlling the disease. In addition, the use of vaccines to control
the TB in wildlife reservoirs of infection could be very valuable in
limiting the spread of infection to domestic livestock andM. bovis
bacille Calmette-Guérin (BCG) was registered for intramuscular
administration to badgers in the UK in 2010. Evidence of the
use of a vaccine to control a disease in wildlife has been shown
from the success of using vaccination to control rabies in foxes
in Europe (12). BCG vaccine is the only registered TB vaccine
for humans and was developed by Calmette and Guérin from a
strain of M. bovis originally isolated by Nocard from a case of
tuberculous mastitis. Following serial passage of the strain on ox
bile glycerine-potatomedium for 230 passages, between 1908 and
1919, this variant strain was shown to be attenuated in animals
and conferred resistance to challenge of animals with virulent
M. bovis and M. tuberculosis [reviewed in (13)]. The strain
was distributed to many countries in the 1920s and continuing
passage in differing conditions produced a considerable number
of daughter strains, with varying antigenic profiles (14).
Vaccination of humans commenced in 1921 and in a meta-
analysis, vaccination of newborns and infants significantly
reduced the risk of TB by an average of over 50%, although
efficacy ranged from 0 to 80% (15). Many field trials of BCG
vaccination of cattle were conducted in the first half of the
twentieth century and the major caveats that restricted the use
of TB vaccines in cattle were that protection was not complete
and vaccination could sensitise animals to respond in traditional
TB diagnostic tests. These problems can now be potentially
overcome by using vaccination integrated with other control
measures and use of diagnostic tests which can differentiate
infected from vaccinated animals (DIVA tests). Currently, there
is very large effort to develop improved TB vaccines for humans,
by developing vaccines which may replace BCG or those that
could boost immunity following initial vaccination with BCG
(16). Research to develop improved TB vaccines for livestock is
following a similar path. Information on the efficacy of BCG in
animals can be of assistance in the development of these new
generation vaccines for use in multiple species. For most wildlife
species, however, vaccination efforts are restricted to the use of a
single-shot vaccine since access to the same individuals in order
to deliver a booster is unrealistic. The focus of this paper is to
provide a review of the efficacy and safety of BCG vaccine in
domestic livestock and wildlife to assist in optimising the use
of BCG vaccine in animals as well as providing a guide for the
development of improved TB vaccines. TB vaccines that do not
use BCG are being studied for some applications, such as a heat-
inactivated M. bovis whole-cell vaccine for wild boar, but these
are not the focus of this review.
VACCINATION OF CATTLE
Historical Studies of BCG
Studies of BCG vaccine in cattle were first reported by Calmette
and Guérin (17) and showed that relatively high doses of BCG
(20mg) could induce protection in cattle against experimental
challenge with M. bovis. In the studies of Calmette and Guérin
(18), intravenous challenge of control calves with virulent M.
bovis resulted in severe generalised TB by 30–60 days. In contrast,
the BCG vaccinates which were challenged remained healthy,
but virulent M. bovis could be isolated from their bronchial
lymph nodes when the animals were killed at 3–4 months post-
challenge. A number of other researchers reported similar results
in experimental challenge studies where BCG vaccination did
not induce absolute immunity, but moderated the severity of
the infection [reviewed in (19)]. A comparison of routes of
vaccination with BCG showed that intravenous, intradermal and
oral routes conferred some resistance to feeding milk containing
large doses of virulent M. bovis, although not greater than
that conferred with subcutaneous vaccination (20). Field studies
of BCG vaccination of cattle using either a subcutaneous or
intravenous route of vaccination showed variable results which
may in part have been influenced by the duration and the potency
of the exposure. Promising results were shown by Rankin (21)
with 86% (37 of 43) non-vaccinates with tuberculous lesions
compared to 33% (22 of 66) for the BCG vaccinates by 8–10
months post exposure. Watson (22) undertook a study over a
longer duration where new-born calves were vaccinated with
BCG subcutaneously (50–100mg dose), fed pasteurised milk for
1–2 months, and then exposed to M. bovis through ingestion of
rawmilk from infected cows or co-habitation with infected cattle.
Frontiers in Veterinary Science | www.frontiersin.org 2 October 2018 | Volume 5 | Article 259
Buddle et al. BCG Vaccine Efficacy and Safety
The study demonstrated that there was good resistance in calves
compared to controls by 1 year post-exposure, but resistance
declined steadily up to reproductive age where there was little
evidence of protection. A number of uncontrolled trials were
undertaken to determine whether BCG vaccination could clear
TB infection in heavily infected herds. Some studies reported
that BCG vaccination eliminated disease over 7 years (23, 24),
while others found this approach reduced the skin test reactivity
and resulted in newly introduced unvaccinated animals (n =
100) remaining skin test negative over a 5 year post-vaccination
period. This approach was judged to be impractical and slow (25).
These early studies indicated that BCG could induce some
protection against TB, although protection was not absolute,
appeared to wane after 1–2 years and vaccination could induce
positive reactivity in the tuberculin test. It was concluded
that TB could be eradicated faster and more efficiently using
“test and slaughter” control programmes than relying only on
vaccination with BCG. However, it was considered that BCG
vaccination could possibly have a role in disease control in
countries where “test and slaughter” programmes could not be
implemented due to economic or social reasons and a number
of trials were conducted in Malawi in the 1970s for this purpose.
Ellwood and Waddington (26) showed that the development of
tuberculous lesions and progressive infection was less in BCG
vaccinates following experimental M. bovis challenge compared
to controls, providing encouragement to proceed with a field
study. In the field trial, 3–12 month old calves were injected
with 107 colony forming units (CFU) of BCG (Glaxo strain) and
revaccinated 6 months later, while alternate calves in each herd
were sham inoculated (27). When the animals were slaughtered
and necropsied 5 years after the commencement of study, no
significant differences could be found in the number of animals
with tuberculous lesions, 36 of 204 (17.7%) in the vaccinates and
44 of 210 (21.0%) in the controls. The numbers of cattle which
were bacteriologically positive and those with lesions at more
than one site were also similar for the two groups.
Possible reasons for the failure to protect in the field trials
could include administration of high doses of BCG (1–100mg
parenterally), very high level of M. bovis exposure, exposure of
young calves to M. bovis through consumption of milk from
infected cows prior to vaccination, lack of long-term protection,
and prior sensitisation to environmental mycobacteria or
helminths. In relation to the dose of BCG, Griffin et al. (28)
demonstrated in deer that parenteral vaccination of a high dose
of BCG (108 CFU) was less effective than doses of 104-107
CFU BCG, whereas higher doses of BCG in badgers appearred
more efficacious (29). This suggests the optimal dose of BCG to
use in any given species will probably need to be determined
empirically. Informative meta-analysis of field trials in cattle
have not been undertaken due to varying doses, vaccination
routes and strains of BCG used, together with different methods
to measure protection and varying levels of exposure to M.
bovis. Furthermore, robustly controlled designs and statistical
analyses of results were rarely undertaken and in most studies,
the vaccinated and non-vaccinated animals were kept on separate
farms.
Recent Studies to Assess Factors
Affecting BCG Vaccine Efficacy in Cattle
Over the past 25 years, a large number of vaccination/challenge
trials have been undertaken in cattle using harmonised models,
allowing comparisons between varying studies with BCG
tested alone or in comparative studies with other vaccines.
Challenge models have focused on using a relatively low
challenge dose of M. bovis (103-104 CFU) administered via
endobronchial/intratracheal inoculation or by aerosol (30, 31).
This has resulted in the development of tuberculous lesions
mimicking those from the natural disease in the lower respiratory
tract. Similar BCG strains have been used (initially Pasteur, then
BCG Danish 1331) and protection assessed by quantitative gross,
histopathological, and microbiological findings.
It is important to determine factors which influence the
efficacy of BCG to optimise the use of the vaccine and Table 1
summarises many of these factors. Results from a number
of studies have shown that doses of 104-106 CFU of BCG
administered parenterally induced equivalent protection (30,
32), while higher doses (108 CFU) were required to induce
protection when BCG was administered orally (33, 34). When
BCG vaccine was administered at optimal doses, protection
induced by the subcutaneous or oral route was very similar,
although an advantage from oral administration of BCG was
slightly lower tuberculin skin test reactivity. Combinations of
BCG by parenteral and mucosal routes has provided mixed
results with no enhancement of protection observed when BCG
was administered subcutaneously and orally on the same day
(35), but a small enhancement in protection with simultaneous
administration of BCG by subcutaneous and endobronchial
routes (36). Pasteur and Danish strains of BCG induced
similar protection, although the kinetics of the cellular immune
response varied with the two strains (37, 38). Calves vaccinated
subcutaneously with the Phipps strain of BCG had lower mean
rank for the total number of tuberculous lesions following a
high challenge dose of M. bovis (105 CFU) delivered by aerosol
compared to controls, although this difference was not significant
(46). Neonatal or very young calves were protected at least
as well as older calves (39, 40). In one study, natural pre-
sensitisation to environmental mycobacteria appeared to have
an adverse effect on subsequent immunity induced by BCG
vaccine, with less protection induced compared to that for two
other attenuated M. bovis vaccines (41). While in another study,
there was evidence that M. avium exposure induced partial
protection againstM. bovis infection, which could possibly mask
subsequent immunity induced by BCG (42). Studies in guinea
pigs andmice have provided additional information on the effects
of pre-sensitisation with environmental mycobacteria where
some strains of M. avium masked or blocked any protective
effect induced by BCG vaccination, while other strains had no
effect (47, 48). Studies in Northern Ireland indicated that co-
infection of cattle with a liver fluke, Fasciola hepatica, and BCG
resulted in a suppression of Th1 type immune responses to BCG,
potentially affecting immunity induced by BCG vaccination (49).
Vaccination of cattle with BCG 3 weeks after an experimental
challenge with M. bovis, did not produce a beneficial effect,
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nor increased tuberculous pathology (45). Protection against
experimental challenge was shown to be effective at ≤12
months post-vaccination, but had waned by 24 months post-
vaccination (43). Together these studies suggest that immunity
wanes between 1 and 2 years post-vaccination when protection is
measured in a stringentM. bovis challenge model.
Two studies report the effect of revaccination with BCG. In
the first study, calves vaccinated within 8 h of birth or at 6
weeks of age showed a high level of protection against M. bovis,
while those vaccinated within 8 h of birth and revaccinated at 6
weeks of age had reduced protection (39). The revaccinated calves
with the lowest level of protection had the strongest antigen-
specific IFN-γ responses post-initial vaccination, suggesting that
revaccination had induced an inappropriate immune response.
In neonatal calves, antigen-specific IFN-γ responses remain at
elevated levels for longer than those seen in older calves, possibly
due to a more active BCG infection and BCG revaccination
of young calves may be contra-indicated. In contrast, calves
vaccinated with BCG at 2–4 weeks of age and revaccinated at
2 years of age when immunity had waned, showed a significant
level of protection when challenged 6 months later, while those
receiving only the initial vaccine dose were not protected when
challenged at the same time (44).
In the past decade a number of field BCG vaccination
trials or experiments have been undertaken under natural
transmission (in contact) conditions and have provided insights
into the effectiveness of BCG vaccine under different levels of
disease prevalence over varying time periods (Table 2). The field
experiments in Mexico (50) and Ethiopia (51, 52) involved the
exposure of vaccinated and non-vaccinated calves to herds of
cows which had reactor rates of 40% in the Mexican experiment
and 100% in the two experiments in Ethiopia. In the Mexican
experiment, vaccination induced a significant level of protection
against TB and the vaccine efficacy was estimated to be 59.4%.
The level of exposure in the experiments in Ethiopia was
very high with ∼85% of the non-vaccinated calves developing
tuberculous lesions. Despite this high level of exposure, the
vaccine efficacy in the first experiment was considered to be
similar to that in the Mexican experiment and there were
significantly fewer vaccinated animals with lesions and culture
positive for M. bovis as well as significantly more vaccinated
animals that would have passed slaughterhouse meat inspection
than that for the controls (51). The vaccine efficacy in the
second experiment conducted in Ethiopia when measured by
comparing lesioned, culture or histology-positive animals in the
BCG-vaccinated group with naïve controls was relatively low
(around 30%) (52). However, in this last experiment, the severity
of pathology and dissemination of M. bovis was significantly
lower in the vaccinated, infected animals compared to that
for the non-vaccinated animals, which could relate to a lower
ability to transmit disease (onward transmission). The difference
between the two Ethiopian experiments was attributed to a higher
prevalence of overt clinical signs of TB in the infected herd in the
second experiment.
A large field trial was undertaken in New Zealand to evaluate
the efficacy of BCG vaccine administered orally (53). Free-
ranging, vaccinated and non-vaccinated cattle were stocked
at low densities and were naturally exposed to M. bovis for
periods of 1–4 years from tuberculin reactor cattle (reactor
herd prevalence of 5–10%) and a wildlife reservoir of infection
(brushtail possums). BCG vaccine was administered orally to
cattle in an attempt to reduce tuberculin skin test reactivity.
This trial included 1,286 cattle and at slaughter the prevalence
of infection was 4.8% among vaccinates and 11.9% in non-
vaccinates. The overall vaccine efficacy was estimated to be
67.4%, but higher for those killed within 2 years post-vaccination
(77.4%). Vaccination also appeared to slow the progression of TB,
with infected vaccinates more likely to have no visible lesions and
less likely to have a high lesion score.
In summary, the field experiments and trials have shown
that BCG vaccination can markedly reduce the number of cattle
infected with M. bovis, which is different to that seen in the
experimental challenge trials where vaccination only reduced the
severity of the disease. However, an exception was in the field
trial when there was a very high exposure to M. bovis (52). With
the longer exposure periods, there appeared to be a waning of
immunity after 2 years (53).
Differentiating Infected From Vaccinated
Animals (DIVA) Tests
It is well-established that vaccination with BCG can compromise
the interpretation of the tuberculin skin test, which serves as
the primary surveillance test for “test and slaughter” bovine
TB control strategies. Using the single intradermal comparative
cervical test, 80% of BCG-vaccinated calves were shown to
react in the tuberculin skin test at 6 months post-vaccination,
but decreasing to 10–20% by 9 months post-vaccination (54)
and in a another study, the maximum skin test reactivity was
observed after 5 weeks, but disappeared completely by 18 months
after vaccination (55). Positive responses were also observed in
the caudal fold skin test at 6 months after BCG vaccination
compared to that for a corresponding control group, but there
were no differences between the groups by 12 months after
vaccination (44). DIVA tests will be required for countries
intending to use BCG vaccination alongside conventional “test
and slaughter” control strategies. DIVA tests have now been
developed using antigens from the M. tuberculosis complex
which are not expressed or secreted by BCG and can be used
instead of bovine PPD in the whole blood IFN-γ or skin tests.
Two of the antigens used in the DIVA tests are the ESAT-6
and CFP10 proteins, which are encoded in the RD1 region of
M. tuberculosis andM. bovis, but not in BCG, which has lost this
region of its genome (56–58), and a third antigen, Rv3615c, which
is not located in the RD1 region, but its secretion is dependent
on the esx-1 secretion system located in the RD1 region (59). A
recent evaluation of the whole blood IFN-γ test incorporating
ESAT-6, CFP10, and Rv3615c indicated that the sensitivity was
similar to that with the comparative tuberculin readout using
avian and bovine PPD. When tested in non-infected animals,
both the DIVA and tuberculin readouts gave similar specificities
of between 97 and 99%. The relative specificity of the DIVA
blood test was also high (95%) in BCG-vaccinated cattle and was
significantly greater than that observed for the tuberculin readout
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(71%) (60). One scenario to use the DIVA blood test would be to
re-test tuberculin-positive cattle; alternatively, it is also possible
to use these antigens in a skin test rather than the IFN-γ test.
The DIVA skin test in cattle has now been shown to have a
high sensitivity for M. bovis-infected cattle, to a similar level
than that for the comparative cervical skin test in non-vaccinated
cattle while not compromised by vaccination with BCG or with
vaccines against Johne’s disease (61, 62).
VACCINATION OF GOATS
TB infection of goats is caused by M. bovis or M. caprae
and in the natural disease lesions are predominantly found in
the lungs and associated lymph nodes, indicating an aerosol
route of infection (63). The disease is responsible for economic
losses in endemic areas and infected goats may be a source of
TB for cattle or humans. Caprine TB is present in a number
of European countries, but currently there are no caprine
TB control campaigns in the European Union. To determine
protective efficacy of vaccines, gross andmicroscopic lesions have
been assessed by qualitative and quantitative analyses, together
with mycobacterial culture from lung-associated lymph nodes.
The precise determination of the total lung lesion burden related
to total lung volume has been achieved using multi-detector
computed tomography (64).
BCG Danish vaccine administered subcutaneously at a dose
of 5 × 105 CFU was shown to be safe and no shedding
of BCG was detected in the faeces of vaccinated kids or in
the milk of vaccinated, lactating goats (65). BCG was isolated
from a lymph node draining the site of vaccination from
one kid at 8 weeks post-vaccination, but not from any goats
at 24 weeks post-vaccination. A single dose of BCG vaccine
administered subcutaneously to goats was shown to significantly
induce protection against an endobronchial challenge with M.
caprae, with reductions in pulmonary pathology and bacterial
load. Vaccination with BCG appeared to prevent haematogenous
dissemination of mycobacteria with extra-thoracic TB lesions
only found in non-vaccinated goats (66). A comparison of
parenterally administered BCG and heat-inactivated M. bovis
vaccines showed that both vaccines provided similar levels of
protection against a M. caprae experimental challenge, with
a reduction in the volume of thoracic TB lesions and extra-
pulmonary lesions compared to non-vaccinates (67). Use of
mycobacterial DIVA reagents, ESAT-6 and CFP10, in the
IFN-γ test was able to differentiate TB-infected from BCG-
vaccinated goats. A field BCG vaccination trial was recently
undertaken in a herd of goats infected with M. caprae (68).
Twenty-three goat kids were vaccinated subcutaneously with
105 CFU of BCG Danish, with a further 22 kids serving
as non-vaccinated controls. Two months later, the kids were
mixed with a herd of goats which had a TB reactor rate
of 79%. Sixteen months later, all trial goats were killed and
necropsied. Vaccination significantly reduced the number of
animals with TB lesions compared to that for non-vaccinates
(35 and 77% respectively; representing a vaccine efficacy of
53%) and when extrapulmonary cases were considered, the
reduction were even higher (17 and 68%, respectively; vaccine
efficacy of 75%). Vaccination has been seen as a valuable long-
term control prospect, reducing the TB prevalence prior to
starting a test and slaughter eradication programme which
would reduce economic costs for producers and the public
sector.
VACCINATION OF SHEEP
Sheep have traditional been considered a rare host for the M.
tuberculosis complex, but can be part of a multi-species system
whichmaymaintain TB in a region, at least in mixed farms where
sheep cohabit with TB-infected cattle and/or goats (69). In a
trial where lambs were vaccinated parenterally with BCG Danish
and subsequently challenged endobronchially with M. caprae,
the vaccinated lambs had a significant reduction in gross lesions
compared to the non-vaccinated controls (70). All challenged
lambs developed gross lesions in the respiratory system, which
were similar to those observed in goats experimentally challenged
withM. caprae at a similar dose.
VACCINATION OF DEER
TB in farmed and feral deer is predominantly caused byM. bovis,
and in the USA and Spain, feral deer also serve as a wildlife
reservoir of M. bovis infection, acting as a source of infection
for domestic livestock (6, 10). Deer serve as important domestic
livestock species, farmed predominantly for the production of
venison, while feral deer are valued for hunting. Tuberculous
lesions are commonly described as liquefied or abscess-like in
contrast to the caseous nature of the lesions seen in cattle and
goats (71, 72). The most frequent site of the tuberculous lesions
is in the retropharyngeal lymph nodes, followed by lesions in the
lungs and associated lymph nodes as well as in the mesenteric
lymph nodes (73). BCG vaccination studies of deer has been
undertaken to assess whether vaccination could be an effective
method of protecting farmed deer from TB and in feral deer to
prevent reinfection back into cattle herds.
Studies of BCG vaccine in red deer have shown that a
single dose of BCG administered subcutaneously to 3 month
old deer could reduce disease severity, while revaccinating deer
at intervals of 8–16 weeks intervals induced protection against
infection, but not at an interval of 43 weeks (74). Increasing
the time period between booster dose and M. bovis challenge
from 6 to 26 or 52 weeks had no significant effect on protection.
Two doses of 104-107 CFU of BCG induced protection against
TB, but less with a dose of 108 CFU and killed BCG in a
mineral-in-oil adjuvant induced no protection (28). A study
in red deer in Spain compared oral administration of BCG
Danish (108 CFU) with oral administration of heat-inactivated
M. bovis, 107 bacilli, followed by an experimental challenge
with M. bovis (75). Only the heat-inactivated vaccine induced a
significant reduction in lesion pathology compared to that for
the non-vaccinates, however, the results were constrained by very
small group sizes (5 animals/group). Neither vaccine induced a
bovine PPD IFN-γ response post-vaccination. Parenteral BCG
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administered at a dose of 106 CFU or oral BCG at 108 CFU
induced a similar degree of protection in white-tailed deer
(76). Parenteral vaccination with either BCG Danish or Pasteur
resulted in decreased disease severity, without sterile immunity
(77). A booster dose 6 weeks later did not raise the level of
protection (78). BCG was shown to persist for 3–9 months
in lymphoid tissues of deer vaccinated parenterally or orally
(79). Evidence has been provided of transmission of BCG from
parenterally vaccinated deer to in-contact, non-vaccinated deer
(77, 79). In another study, deer orally vaccinated with 109 CFU
BCGDanish were housed with non-vaccinated deer for 27 weeks.
There was immunological evidence of transmission of BCG to
the non-vaccinated animals, but no BCG could be isolated from
the tissues of either group of animals when killed 27 weeks after
vaccination (80). There was no evidence (immunologically or
by culture) of transmission of BCG to the cattle which were
exposed to the room previously occupied by the vaccinated deer.
Complications can occur with the delivery of oral vaccine baits
to feral deer as the provision of supplementary feed to feral
deer can lead to large numbers of deer congregating together
resulting in the spread of TB (81), also there are concerns
about non-target uptake of live vaccine baits, particularly by
cattle. Simulation modelling has examined the potential role that
vaccination could play in control programmes to minimise cattle
herd breakdowns (82). Vaccination of 50–90% of susceptible deer
within a 5 km radius of cattle farms was predicted to result in a
95% probability of having no cattle herd breakdowns in 15–18
years.
BCG VACCINATION OF WILDLIFE
The requirements for a vaccine for wildlife differ to those for
domestic livestock in that preferentially, the vaccine would be
self-administered via an oral route and animals would only
receive a single vaccination. Vaccination should prevent the
spread of infection to other wildlife or livestock, but complete
protection against infection would not be necessary. Recent
studies in multiple wildlife species have shown that BCG vaccine
can fulfil these requirements and provide protection against TB
(Table 3).
Vaccination of Brushtail Possums
The brushtail possum is the major wildlife reservoir of M. bovis
infection in New Zealand as well as declared as a noxious pest.
Possums are highly susceptible to M. bovis infection and lesions
are found predominantly in the lungs and superficial lymph
nodes. Culling of possums by trapping and poisoning has been
a major contributor to the dramatic reduction in the numbers of
infected cattle over the past 20 years (11). Vaccination of possums
against TB has the potential to be an effective TB control measure
when it is not suitable to cull possums such as near urban areas.
BCG vaccination of possums via a number of different routes
including subcutaneous, intranasal and oral have induced a
significant level of protection against experimental M. bovis
challenge by intratracheal and aerosol routes (83, 93). Oral
administration of BCG via baits would be the preferred route
of administration of BCG vaccine to wild possums, but it
was shown that direct administration of BCG intragastrically
was less effective compared to administered by the same
route and mixed with a drug to reduce gastric acidity or
when administered intraduodenally (94, 95). To increase the
efficacy of oral administered BCG vaccine, the BCG bacilli were
encapsulated in a lipid matrix which protected the bacteria
from degradation in the acidic stomach environment, resulting
in improved protection against a M. bovis challenge as well
as increasing shelf life of the vaccine in the field (83, 96).
Vaccine-induced immunity was shown to wane between 6
and 12 months post-vaccination following oral vaccination
and there were no differences between BCG doses of 107
and 108 CFU or between Danish and Pasteur strains of
BCG (97). A more recent study indicated that protection
against an experimental M. bovis infection extended out to
TABLE 3 | Summary of BCG vaccine efficacy studies in wildlife.
Species/Country Route
†
Challenge type Vaccine
efficacy‡
Notes/Particular issues Key
references
Bushtail possum/New Zealand O,M, P Aerosol, + High vaccine cost compared to that for poisons (83)
natural exposure + (84)
European badger/ UK, Ireland O,M, P Endobronchial,
Natural exposure
+
+
Parenteral vaccine licensed (BadgerBCG). For
an oral vaccine: demonstration of consistent
protection
(29, 85)
(86–88)
White-tailed deer/ USA O,P Intratonsilar + BCG persistence in tissues, bans on
supplementary baiting, non-target bait uptake
(76, 77)
Eurasian wild boar/Spain O Oral + Non-target bait uptake (89)
Natural exposure ± Regulatory issues (90)
Ferret/New Zealand O,P Oral ± Rarely maintenance host for M. bovis (91, 92)
African buffalo/ South Africa P Intratonsilar – Practicality of vaccine delivery in the field (7)
†
Vaccination route, O, oral; M, other mucosal; P, parenteral.
‡Vaccine efficacy, + protection, ± partial protection, – no protection.
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28 months post-vaccination (98). BCG bacilli were shown
to be stable in the lipid matrix for 7 weeks under room
temperature conditions and 3–5 weeks under field conditions
in a forest/pasture habitat, when maintained in weather-proof,
bait-delivery sachets. Furthermore, uptake of oral bait placebo
vaccines was shown to be high with 85–100% of wild possums
accessing baits at bait densities of 40–80 sachets/hectare (96).
Possums consuming oral bait BCG vaccine, containing 108 CFU
of BCG, displayed no adverse clinical signs, but shed relatively
low concentrations of BCG in their faeces, 102-104 CFU/g
faeces, for up to a week and BCG could be isolated from their
mesenteric lymph nodes for up to 8 weeks post-vaccination
(99).
Two field trials have been undertaken in possums to determine
efficacy of BCG vaccine against natural exposure to M. bovis
infection. In the first trial, BCG vaccine was administered
intranasally and intraconjunctivally (total dose of 106 CFU of
BCG Pasteur) to possums trapped in the field, with an equivalent
number left non-vaccinated. After vaccination, the animals were
released back into the field site, which was endemic for TB in
wildlife (100). The animals were trapped, examined for clinical
TB and released again every 2 months. Two years after the start
of the study, possums were recaptured, killed and examined
for TB lesions. Vaccination significantly reduced the proportion
of possums infected with M. bovis (4/149 for vaccinates and
13/151 for non-vaccinates), with a vaccine efficacy of 69% for
prevention of TB. The second field study was of a similar design,
but with BCG vaccine administered orally in a lipid matrix
(total dose 108 CFU BCG Danish). Again, there was a significant
reduction in the proportion of infected possums in vaccinates
(1/51) compared to that for the non-vaccinates (12/71), with a
vaccine efficacy of 95% for prevention of TB (84). In contrast
to the experimental challenge studies, protection against natural
exposure to M. bovis vaccination resulted in protection against
infection. The major constraint for the use of BCG vaccine in
possums in New Zealand is cost of the vaccine compared to
that for poisons, particularly when possums are considered as a
noxious pest.
Vaccination of Badgers
The European badger is the major wildlife reservoir of M. bovis
infection in Great Britain due to their relative abundance and
ecology, the prevalence of infection and presentation of TB
pathology compared to other sylvatic species (101, 102). Options
for preventing the transmission ofM. bovis from infected badgers
to cattle are limited to minimising the potential for contact
between them (biosecurity), reducing the number and density
of infected badgers via selective and non-selective culling, and
vaccination [reviewed in (103)]. Badgers are protected by law
in the UK and Ireland which limits the public acceptability
and practicality of culling and for disease control, and culling
of badgers in England and Ireland has sometimes delivered
conflicting results that likely reflect subtle differences in the
epidemiology of the disease locally (104). Vaccination of badgers
against TB has the potential to be an effective TB control measure,
especially in combination with other control measures (105) and
considerable progress has been made in testing the efficacy of
BCG vaccine in badgers.
BCG vaccine has been administered to badgers via a
variety of routes, including subcutaneous, intramuscular and
mucosal (conjunctival and oral) and vaccination by all these
routes has induced significant protection against experimental
endobronchial challenge with M. bovis [reviewed in (103)].
The use of BCG to vaccinate badgers against TB in the
UK by the intramuscular route was licensed by the UK
Competent Authority (Veterinary Medicines Directorate) in
2010 as BadgerBCG and is available for use by veterinarians and
trained lay vaccinators under prescription from a veterinarian.
Licensing of BadgerBCG required evidence of vaccine safety and
efficacy and laboratory and field studies showed that vaccination
of badgers by injection with BCG was both safe and significantly
reduced lesions of TB caused by M. bovis (29, 106). Protection
was incomplete, in that M. bovis infection of vaccinated badgers
still produced either visible pathology or M. bovis was isolated
from organs at necropsy. Results from a 4-year field study of BCG
in wild badgers were consistent with the direct protective effect of
BCG observed in experimental studies. Individual badgers that
initially tested negative to a panel of diagnostic tests, presumed
uninfected, were significantly less likely to subsequently test
positive to serological and immunological tests for TB following
vaccination, compared to non-vaccinated control animals (86,
107). Furthermore, non-vaccinated cubs captured in vaccinated
social groups were significantly less likely to test positive to
TB when more members of their group had been previously
vaccinated. The most plausible explanation for this result is that
BCG had caused a herd immunity effect, with the rate ofM. bovis
transmission being more effectively reduced in social groups
where a higher proportion of animals had been vaccinated.
A practical limitation to the extensive use of BadgerBCG is
the need to trap badgers before the vaccine can be injected and
the use of an oral bait delivery system would be advantageous.
BCG has been incorporated in a wide variety of baits, including
encapsulation in the same lipid matrix used to deliver BCG orally
to possums. Administration of BCG orally to captive badgers,
either directly to the back of the throat, or indirectly via ingested
bait has been shown to protect badgers against experimental
challenge with M. bovis and there was no difference in the levels
of protection induced by Pasteur and Danish sub-strains of BCG
(85, 108). To assess the vaccine safety, badgers were orally dosed
with 109 CFU of BCG, followed 14 days later by a single oral
dose of 107 CFU BCG (109). No adverse physical effects were
observed, nor effects on the social behaviour and feeding habits of
the vaccinated animals. BCG was cultured from the faeces of two
of nine vaccinated animals (102 CFU/g) ∼48 h after the higher
dose of BCG was administered and by one of the nine vaccinated
animal (80 CFU/g) ∼24 h after receiving the lower dose of BCG.
No evidence was found for the transmission of BCG to non-
vaccinated, sentinel, badgers housed with the vaccinated animals
despite the occasional excretion of BCG in faeces. The target dose
of BCG for the oral vaccination of badgers is yet to be defined.
A field trial was recently completed in Ireland that provided
the first estimate of oral BCG efficacy under field conditions
(87). Lipid-encapsulated BCG was delivered to the back of the
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throat of anaesthetised badgers, whilst other badgers received
only the lipid as placebo. The study area was divided into
three equally representative zones with different proportions
(0, 50, and 100%) of the badger population in each zone
being vaccinated with either BCG or placebo. Attempts were
made to capture badgers every 6 months and between the
first two capture periods the vaccine efficacy was estimated to
be 36%, while it was 84% for capture periods 3–6. Among
the vaccinated badgers that seroconverted, the median time
to seroconversion (413 days) was significantly longer when
compared with non-vaccinated animals (230 days). In addition,
there was a significant reduction in the proportion of animals
presenting with M. bovis culture confirmed lesions in the fully
(100%) vaccinated zone (9%), compared with the non-vaccinated
(0%) zone (26%).
Vaccination of Wild Boar
Wild boar serve as the main wildlife reservoir of the M.
tuberculosis complex (MTC) in the Mediterranean regions of
the Iberian Peninsula, Spain and TB prevalence in wild boar
has been associated with TB occurrence on cattle farms (110,
111). Wild boar are widespread in Eurasia and can be found
in high densities, particularly on hunting estates (112). These
animals are highly susceptible to MTC infection and lesions
are most frequently found in the mandibular lymph nodes,
although generalised disease is often seen, with involvement
of the lungs and thoracic lymph nodes (113). Direct contact
between wild boar and other species is thought to be very
rare in Mediterranean habitats and inter-species transmission of
MTC involving wild boar is considered to occur indirectly at
locations such as waterholes (114). Although, transmission of
TB between wild boar and cattle could be minimised by culling
of wild boar and preventing inter-species contact, vaccination
could be a more cost-effective and sustainable disease control
measure.
Oral vaccination with BCG Danish (106 CFU/dose) vaccine
has produced significant protection (70–80% lesion score
reduction) in laboratory challenge trials (89, 115). The focus has
been to vaccinate piglets as they are less likely to be infected
and can be targeted by appropriate timing of bait delivery and
with the use of a patented bait delivery system that reduces
uptake by non-target species and excludes adult boar (116). In
a recent safety study, wild boar were dosed with an oral bait
containing 106 CFU of BCG and groups of vaccinated animals
were killed at 1, 3, 5, and 9 months post-vaccination (117).
No adverse clinical signs were observed and tissues collected
from the animals were culture negative for BCG. A field trial
undertaken from 2012 to 2016 tested the uptake rates and efficacy
of orally delivered BCG and heat-inactivatedM. bovis vaccines in
high prevalence settings (40–80% wild boar infection prevalence)
in Montes de Toledo, Spain (90). The two vaccines were tested at
different sites, one managed and one natural (or unmanaged) site
for each vaccine, with an additional 15 non-vaccinated control
sites. Vaccine baits were deployed using selected piglet feeders
and the uptake rates were 50–74% in natural sites and 89–92%
in managed sites. A significant reduction in the TB prevalence
was only seen from one vaccinated site: heat-inactivated M.
bovis vaccine in the managed site; with a 34% reduction in the
prevalence of animals with lesions. A limitation of the study was
that vaccines were deployed at different sites and efficacy was
measured by the change in TB lesion prevalence compared to
time zero.
Vaccination of Ferrets
In New Zealand, ferrets (Mustela furo) can become infected
with M. bovis via feeding on tuberculous carcasses, particularly
possums and potentially can become a source of infection for
other wildlife or cattle (118). In most circumstances, ferrets are
simply spill-over hosts and as yet, there is no confirmation that
ferrets act as true maintenance hosts in New Zealand. Rather,
ferrets could be characterised as extended spill-over hosts in
whichM. bovis infection originally acquired from possums could
occasionally cycle within a ferret population before disappearing
(119). Vaccination has been considered as a possible control
measure for ferrets and in the first of two vaccination trials,
ferrets orally vaccinated with BCG incorporated into dietary
meat were partially protected against oral challenge with virulent
M. bovis (91). In the second trial, vaccination of ferrets with
BCG by the subcutaneous route resulted in reduced severity
of disease following experimental infection with M. bovis
(92).
Vaccination of African Buffalo
M. bovis infection is currently endemic in the Greater Kruger
National Park Complex and the Hluhluwe-iMfolozi Park (120,
121), as well as in several private farms and conservancies
in South Africa (122). African buffaloes are likely to be
major maintenance hosts of TB (123) and play an important
role in spill-over infection to other wildlife species, and of
particular importance is spread of infection to predators (lions),
large browsers (white rhino) and other co-located species
such as kudu, baboons, and warthogs (124). In addition,
there has been “spill-back” to domestic cattle (125). As “test
and cull” is not a viable option for free-ranging buffaloes
due to logistical impracticality and the animals’ extensive
geographical range, vaccination remains the only realistic
alternative.
A preliminary vaccine trial was undertaken in semi-free-
range buffalo to assess the efficacy of BCG vaccine. Two
doses of BCG were administered subcutaneously (107 CFU
of BCG) and the buffaloes were challenged with virulent M.
bovis via the intratonsilar route. The study did not reveal
significant differences in the number of lesioned animals between
the vaccinated and control groups (7). There were various
contributing factors which could have played a role in the
perceived negative results such as the age of vaccinated animals
with the majority being older than 12 months at the start of the
study, the route of vaccine application, challenge dose, exposure
to non-tuberculous mycobacteria and stress on the animals with
the grazing limitations. Future studies should aim to determine if
BCG vaccination could reduce TB in vaccinated herds compared
to non-vaccinated herds by targeting buffaloes <12 months old
andmonitoring over a period of 5–10 years in order to determine
true disease status. If successful, vaccination could have a positive
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cascading effect, reducing M. bovis disease rates in other animal
species. The available data does not suggest any risk to “off-target”
species from BCG delivery, which reduces the ethical barriers to
implementation.
SAFETY OF BCG VACCINE IN TARGET
AND NON-TARGET SPECIES
BCG vaccine is one of the most widely used human vaccines,
with 100 million children receiving the vaccine annually and
remains one of the safest vaccines available. Reports of adverse
reactions arising from BCG vaccination of children are relatively
uncommon and a review of reactions to BCG vaccine in humans
and animals has recently been provided by Murphy et al. (126).
More severe reactions to BCG vaccine in humans were often
the result of vaccination of immune-compromised individuals
and factors influencing the development of adverse reactions
included the potency and dose of the vaccine strain, route of
delivery, age and immune status of the host and skill of the
operator administering the vaccine. The most common reactions
were local and regional reactions, which were generally self-
limiting where suppurative lymphadenitis and abscesses were the
most frequent occurring reactions.
BCG vaccine has been tested in a large number of animal
species (Table 4) and relatively minor adverse clinical signs have
been observed in some cases. In cattle, Francis (19) described
local lesions arising following subcutaneous administration of
large doses of BCG, similar to those seen with inoculation of
large doses of dead bacilli, but no progressive lesions were
produced and bacilli were gradually eliminated from the body.
Repeat passaging of BCG vaccine in animal species is still to be
undertaken to ensure no reversion to virulence, but the evidence
from its use in humans for nearly a century has emphasised the
safety of the vaccine.
Local abscesses or nodules have been observed following
subcutaneous injections of BCG in a number of other animal
species and these resolved relatively quickly (Table 4). No adverse
effects have been observed after oral administration of BCG
in animals other than cervical lymphadenitis observed in mice
(127), similar to a reaction observed occasionally in young
vaccinated children (126). Following oral dosing with BCG of
possums and badgers, transient shedding of low numbers of BCG
in faeces was observed (99, 109). Transmission of BCG from
vaccinated animals to in-contact non-vaccinates has only been
recorded in white-tailed deer (79). There is a risk that distribution
of oral baits containing BCG for wildlife could lead to uptake by
non-target animal species such as cattle, resulting in a subsequent
positive tuberculin skin test response and therefore special care
with regards to bait distribution is essential. The chance of
cattle becoming infected with BCG from faecal contamination
of pasture or feed from vaccinated wildlife would be very rare
as tuberculin skin test reactivity following oral administration
of BCG to cattle has only been recorded with high doses of
BCG (≥107 CFU) (34). Similar to the situation in humans, BCG
vaccine is considered to be a safe vaccine in all animal species
tested.
TABLE 4 | Studies of safety of BCG vaccine of different strains in target and non-target animal species.
Animal species BCG
strain
Adverse clinical signs Key references
Mouse Pasteur Cervical lymphadentitis—oral, None—S/C (127)
Hamster Tice Pleural reaction—I/P high dose (128)
Guinea pig Tice None—I/D (129)
Rabbit Phipps Local abscess—I/D (130)
Dog Tice Mild pleural reaction—I/P (128)
Monkey Pasteur Axilliary lymphadenitis- high dose I/D (131)
Local draining abscess—medium dose S/C
Sheep Danish None—S/C (70)
Horse Pasteur None—intralesion injection (132)
Goat Danish None—S/C, no shedding in milk or faeces (65)
Cattle Pasteur Local swelling at injection site—S/C (19)
White-tailed deer Danish None—S/C, Oral, BCG persisted in draining LNs (12 months), transmission to in-contacts (79, 80)
Red deer Pasteur None—S/C, persisted in draining LNs (14 wks) (133)
Possum Danish None—Oral, shedding in faeces (1 wk), persisted in mesenteric LNs (8 wks) (99)
Pasteur None—Aerosol, S/C (93)
Badger Danish None—Oral, single and repeat dosing, shedding in faeces (48 h) (109)
Danish I/Mus, S/C, single, and repeat injection, local swelling at injection site (106)
Wild boar Danish None—low dose oral, BCG not re-isolated (117)
Ferret Pasteur None—Oral, S/C (91, 92)
African buffalo Pasteur None—S/C (7)
Vaccination route: I/D, intradermal; I/M, Intramuscular; I/P, Intrapleural; S/C, Subcutaneous.
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CONCLUSIONS
Experimental challenge studies in domestic livestock including
cattle, goats, sheep and farmed deer have demonstrated that BCG
vaccination can moderate the severity of the disease, while field
trials in cattle and goats have indicated that vaccination can
also reduce infection. No single vaccine has been shown to be
better than BCG in cattle, although combinations of BCG with
various subunit TB vaccines have produced encouraging results
and could have application in the future [reviewed in (2, 134)].
Vaccination of cattle with BCGwould have greatest application in
countries where “test and slaughter” strategies are not affordable
or socially acceptable and in this situation, BCG could play a
role in reducing the spread of bovine TB. It is well-recognised
in humans that BCG confers some non-specific protective effects
against other pathogens (135), but this has yet to be evaluated in
cattle. Improvement in general health of animals per se and/or
increased productivity post-BCG vaccination could potentially
have benefits in developing countries. Strategic use of BCG
vaccine for livestock could also be implemented in regions where
wildlife serve as reservoirs of infection, particularly where it is not
feasible to contain the spread of infection from wildlife. In these
situations, DIVA tests, particularly skin tests utilising specific M.
bovis antigens, could be used in livestock in association with
vaccination to allow vaccination to be integrated with “test and
slaughter” control measures.
A number of recommendations can be made from the
experimental challenge and field experiments in cattle. Calves
should be vaccinated with BCG as young as possible, optimally
by 2–4 weeks of age, at doses of 105-106 CFU parenterally
or 108 CFU orally and no differences have been detected in
protection induced by two of the most commonly used BCG
strains, Pasteur and Danish. Protection has been shown to wane
between 1 and 2 years post-vaccination and revaccination is
recommended every 1–2 years to maintain levels of immunity.
BCG vaccine has been shown to be safe in cattle and vaccination
of cattle pre-infected with M. bovis is not likely to exacerbate or
cure infection. Vaccination is likely to produce false reactions
in traditional TB diagnostic tests in the first 12 months post-
vaccination and as protection induced by BCG is not complete,
DIVA tests should be used if “test and slaughter” control policies
are in place. It would be preferable to use BCG vaccination in
association with other TB control measures such as minimising
the chance of early exposure to M. bovis by feeding young
calves with colostrum or milk from non-reactor cattle or with
heated milk, segregating reactor and non-reactor cattle into
separate herds and keeping vaccinated calves with the non-
reactor animals.
The field testing of BCG vaccine in possums and badgers
administered via oral or parenteral routes have resulted in the
induction of significant reductions in infection of these animals
and a parenteral BCG vaccine has now been licensed for use
in badgers in the UK. In wild boar, feral deer and ferrets, BCG
vaccine has been shown to induce significant levels of protection
against experimental challenge with TB. Practical systems for
delivery of oral bait TB vaccines to wildlife have now been
established, but further research is necessary to improve oral bait
formulations with appropriate attractants, systems for optimising
bait distribution and avoiding bait uptake by non-target species.
BCG vaccine has been shown to be safe in all animal species
tested, although BCG has been isolated from lymph nodes
draining vaccination sites and from faeces of animals for a
short period following oral vaccination. There was evidence
that vaccinated white-tailed deer could transmit BCG to non-
vaccinated pen-mates, but not to cattle exposed to the room
previously occupied by the vaccinated deer.
In summary, there have been major advances in the past
10–20 years in our understanding of the factors influencing
BCG vaccine efficacy for domestic livestock and wild animals.
To optimise the use of BCG vaccine, it will be important
to continue to field test BCG vaccine in the various animal
species in different environments, husbandry systems and in
the presence of varying levels of disease prevalence as well as
evaluating the practical application of DIVA tests. Although
BCG vaccine may not provide complete protection against
exposure to M. bovis, the protection should be sufficient to
markedly reduce onward transmission to others animals. This
feature could ensure that BCG vaccine could be particularly
valuable for reducing infection in wildlife populations and
in domestic animals where infection is currently very high
and where “test and slaughter” control strategies are not able
to be undertaken. There are numerous technical hurdles still
to be overcome before an economically viable oral vaccine
for use in badgers in the UK might be available. In the
meantime it is beholden on stakeholders to make the best use
of the existing tools available, this includes the intramuscular
BadgerBCG vaccine. Cattle BCG vaccination in countries using
“test and slaughter” control strategies also face significant
hurdles. For example, a BCG vaccination-compatible DIVA
test needs to be validated to allow vaccination to continue
alongside traditional “test and slaughter” control programmes;
currently BCG vaccination is prohibited under EU and some
other countries’ legislation and this would need to change; finally,
cost-benefit analyses would decide whether deployment would
proceed.
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